Literature DB >> 7781922

Targeted vectors for gene therapy.

N Miller1, R Vile.   

Abstract

Successful gene therapy requires not only the identification of an appropriate therapeutic gene for treatment of the disease, but also a delivery system by which that gene can be delivered to the desired cell type both efficiently and accurately. Reductions in accuracy will inevitably also reduce efficiency since fewer particles will be available for delivery to the correct cells if many are sequestered into nontarget cells. In addition, the therapy will have net benefit to the patient only if gene delivery is sufficiently restricted such that normal cells are left unaffected by any detrimental affects of bystander cell transduction. Here we review how currently available delivery systems, both plasmid and viral, can be manipulated to improve their targeting to specific cell types. Currently, targeting is achieved by engineering of the surface components of viruses and liposomes to achieve discrimination at the level of target cell recognition and/or by incorporating transcriptional elements into plasmid or viral genomes such that the therapeutic gene is expressed only in certain target cell types. In addition, we discuss emerging vectors and suggest how gene therapy delivery systems of the future will be composites of the best features of diverse vectors already in use.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7781922     DOI: 10.1096/fasebj.9.2.7781922

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  30 in total

Review 1.  Retroviral vectors.

Authors:  K M Kurian; C J Watson; A H Wyllie
Journal:  Mol Pathol       Date:  2000-08

2.  Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery.

Authors:  Deirdre P McIntosh; Xiang-Yang Tan; Phil Oh; Jan E Schnitzer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 3.  Imaging gene expression: principles and assays.

Authors:  S S Gambhir; J R Barrio; H R Herschman; M E Phelps
Journal:  J Nucl Cardiol       Date:  1999 Mar-Apr       Impact factor: 5.952

4.  Live dynamic imaging of caveolae pumping targeted antibody rapidly and specifically across endothelium in the lung.

Authors:  Phil Oh; Per Borgström; Halina Witkiewicz; Yan Li; Bengt J Borgström; Adrian Chrastina; Koji Iwata; Kurt R Zinn; Richard Baldwin; Jacqueline E Testa; Jan E Schnitzer
Journal:  Nat Biotechnol       Date:  2007-03-04       Impact factor: 54.908

Review 5.  From nutraceuticals to pharmaceuticals to nanopharmaceuticals: a case study in angiogenesis modulation during oxidative stress.

Authors:  Shaker A Mousa; Dhruba J Bharali; Donald Armstrong
Journal:  Mol Biotechnol       Date:  2007-09       Impact factor: 2.695

6.  Gene therapy, early promises, subsequent problems, and recent breakthroughs.

Authors:  Saeideh Razi Soofiyani; Behzad Baradaran; Farzaneh Lotfipour; Tohid Kazemi; Leila Mohammadnejad
Journal:  Adv Pharm Bull       Date:  2013-08-20

Review 7.  Anti-tumor gene therapy.

Authors:  C Cirielli; M C Capogrossi; A Passaniti
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

Review 8.  Retroviral vectors. From laboratory tools to molecular medicine.

Authors:  R G Vile; A Tuszynski; S Castleden
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

9.  Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma.

Authors:  R M Diaz; T Eisen; I R Hart; R G Vile
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 10.  Tyrosine hydroxylase and Parkinson's disease.

Authors:  J Haavik; K Toska
Journal:  Mol Neurobiol       Date:  1998-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.